Had care of arterial hypertension patients been advanced in 2021?

Česká verzia

Authors: Anna Vachulová ¹; Adriana Šimková ²; Slavomíra Filipová ³
Authors place of work: Kardiologická klinika Lekárskej fakulty UK a Národného ústavu srdcových a cievnych chorôb, a. s., Bratislava ¹; Duo medical, s. r. o., Pezinok ²; Národný ústav srdcových a cievnych chorôb, a. s., Bratislava ³
Published in the journal: Vnitř Lék 2022; 68(4): 246-252
Category: Review Articles

Summary

Arterial hypertension (AH) is a very common disease with increasing incidence and prevalence. AH becomes worldwide the main preventable cause of the preventable deaths. Therefore, it is very important to obtain early diagnose and convenient treatment. Still high cardiovascular mortality in Slovakia, where we have a position at the tail compared to other European countries, very closely related to the failure to obtain treatment blood pressure (BP) target ranges. AH rarely occurs in isolation, and often clusters with other CV risk factors such as dyslipidemia and obesity. 2018 ESC/ESH Guidelines for the management of arterial hypertension has brought several new concepts how to manage arterial hypertension. However, it is important to implement the recommendations of the European Society of Cardiology to everyday clinical practice in each country.

Keywords:

obesity – overweight – arterial hypertension – Charter 70/2023 – 2018 ESC/ESH Guidelines for the management of arterial hypertension – adherence to treatment

Zdroje

1. Visseren FL, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC), EHJ. 2021; 42 (34): 3227-3337. https://doi.org/10.1093/eurheartj/ehab4842021 CVD Prevention.

2. www.statistics.sk

3. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396 (10258):1223-1249. doi: 10.1016/S0140-6736(20)30752-2.

4. Kotseva K, De Backer G, De Bacquer D et al. Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC‑EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019;26(8):824-835. doi: 10.1177/2047487318825350. Epub 2019 Feb 10. PMID: 30739508.

5. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339.

6. Hatala R, Nehaj F, Šidlo R et al. Skríning artériovej hypertenzie u dospelých osôb pri návšteve ambulancie všeobecných lekárov na Slovensku – iniciatíva „Charta 70/2023“. Cardiology Lett. 2021;30(3–4):148–158.

7. Niccoli G, Montone RA, Ibanez B et al. Optimized Treatment of ST‑Elevation Myocardial Infarction. Circ Res. 2019 Jul 5;125(2):245-258. doi: 10.1161/CIRCRESAHA.119.315344. Epub 2019 Jul 3. PMID: 31268854.

8. Parati G, Kjeldsen S, Coca A et al. Adherence to Single‑Pill Versus Free‑Equivalent Combination Therapy in Hypertension: A Systematic Review and Meta‑Analysis. Hypertension. 2021 Feb;77(2):692-705. doi: 10.1161/HYPERTENSIONAHA.120.15781. Epub 2021 Jan 4. PMID: 33390044.

9. Šimková A, Výsledky DMTK u pacientov s artériovou hypertenziou v roku 2021, Medicus News 3/3021.

10. Gradman AH, Parisé H, Lefebvre P et al. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013; 61(2):309-18. doi: 10.1161/HYPERTENSIONAHA.112.201566.

11. Strauss MH, Hall AS. Angiotensin Receptor Blockers Do Not Reduce Risk of Myocardial Infarction, Cardiovascular Death, or Total Mortality: Further Evidence for the ARB‑MI Paradox. Circulation. 2017;135(22):2088-2090. doi: 10.1161/CIRCULATIONAHA.117.026112.

12. Taddei S, Bortolotto L Unraveling the Pivotal Role of Bradykinin in ACE Inhibitor Activity. Am J Cardiovasc Drugs. 2016;16(5):309-21.

13. Van Vark LC,Bertrand M, Akkerhuis KM et al. Angiotensin‑ converting enzyme inhibitors reduce mortality in hypertension: a meta‑analysis of randomized clinical trials of renin– angiotensin–aldosterone system inhibitors involving 158 998 patients. EHJ, 2012; 33 (16):2088–2097.

14. Daskalopoulou S., Vilatte R. Effectiveness and Tolerability of Perindopril 3.5 Mg/amlodipine 2.5 Mg Single Pill Combination in Newly Diagnosed Patients With Hypertension. The Simple National Study Across Canada Circ 2020; Suppl 3 (142), A14065.

15. Glezer MG. Antihypertensive Effect of Switching to a Fixed Perindopril/Amlodipine Combination in Patients Ineffectively Treated by Free Sartan‑Containing Combinations. Results of the AVANGARD Study. Kardiologiia. 2019;59(10):31-38. doi: 10.18087/cardio. 2019. 10. n731. PMID: 31615386.

16. Unger T, Borghi C, Charchar F et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 202075(6):1334-1357. doi: 10.1161/HYPERTENSIONAHA. 120.15026.

17. https://www.nice.org.uk/guidance/ng136.

18. Chalmers J, Mourad JJ, De Champvallins M et al. Benefit of Indapamide- based treatment on mortality. Journal of Hypertension 2019; 37, Issue - p e57 doi: 10.1097/01. hjh.0000570928.33807.a8.

19. Glezer MG; FORSAGE Investigators. Antihypertensive Effectiveness of Perindopril Arginine and Indapamide Single‑Pill Combination According to Body Mass Index: Findings from the FORSAGE Study. Cardiol Ther. 2020;9(1):139-152. doi: 10.1007/s40119-020-00162-x.

20. Karpov YA, Gorbumov VM, Logunova NA. Triple fixed‑dose combination in the treatment of hypertension: the results of the Russian observational study TRICOLOR, Russ J Cardiol. 2020; 25(10):104-115.https://doi.org/10.15829/1560-4071-2020-4130.